Keith A. Coffman, MD

Child Neurology, Neurodevelopmental Pediatrics

Keith A. Coffman, MD

Child Neurology, Neurodevelopmental Pediatrics

Director, Movement Disorders Program; Director, Tourette Syndrome Center of Excellence; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Clinical Assistant Professor of Neurology, University of Kansas School of Medicine

Headshot of Keith A. Coffman, MD

Director, Movement Disorders Program; Director, Tourette Syndrome Center of Excellence; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Clinical Assistant Professor of Neurology, University of Kansas School of Medicine

For admissions, consults, and transports.

Areas of Interest

Child Neurology, Neurodevelopmental Pediatrics
Deep Brain Stimulation, Cerebral Palsy, Developmental delay, Movement Disorders, Neurodegenerative Disorders, Neurogenetic Disorders, Tics and Tourette Syndrome

Education and Training

Degree

MD, Pennsylvania State University College of Medicine

Residency

Neurology, Children's Hospital of Pittsburgh

Pediatrics, Children's Hospital of Pittsburgh

Fellowship

Child Neurology, University of Pittsburgh School of Medicine

Certifications

Child Neurology

Neurodevelopmental Disabilities

Practicing Locations

Children's Mercy Adele Hall - Neurology
2401 Gillham Rd Kansas City, MO 64108
View Location
Children's Mercy Hospital Kansas - Neurology
5808 W 110th St Overland Park, KS 66211
View Location
Children's Mercy Northland - Neurology
,
View Location

Scholarly Work

  • Select Publications
  • Generic placeholder image
    Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome.

    As an expert in the treatment of Tourette Syndrome (TS), recently, Dr. Coffman was asked to author an article on the pharmacological treatment of Tourette Syndrome. In collaboration with Dr. Quezada, the paper was published in CNS Drugs Journal, focusing on current approaches and new developments regarding treatment of Tourette Syndrome. The team developed a visual algorithm to help guide the treatment of TS using medication based on the level-of-evidence and side-effects. It has been designed for others to use both inside the U.S. and globally.